Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza will sell Pennsylvania site to investors

by Rick Mullin
May 14, 2022 | A version of this story appeared in Volume 100, Issue 17

Lonza, the Swiss drug services firm, has agreed to sell its particle size reduction and control plant in Quakertown, Pennsylvania, to a group of investors. The site includes two buildings housing nine manufacturing suites and two development suites. The new company, Microsize, employs about 45 people. Investors include Mark Bamforth, founder of Brammer Bio and Arranta Bio, and Bill Mitchell, founder of PCI Pharma Services.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.